Change the brand Change the cost Join the change to carbon neutral All by choosing Bibecfo - the new beclometasone/formoterol combination from Cipla 1-6
This site is intended for Healthcare Professionals only.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to Cipla (EU) Ltd on 0800 0472144, drugsafety@cipla.com
Discover the benefits to your patients and NHS budgets that prescribing Bibecfo may bring1-3
Use this site to learn more about Bibecfo and how it could help you manage your prescribing budget. There is also information available to help support your patients when using their Bibecfo pMDI (pressurised metered dose inhaler).
Bibecfo pMDI is formulated with extrafine beclometasone particles1,2
Extrafine particles allow patients to be maintained on a lower steroid dose than non-extrafine formulations. Data have shown the use of extrafine beclometasone contributes to improved real-life outcome measures when managing asthma and COPD.7-9
All available beclometasone/formoterol combination pMDIs (Bibecfo, Fostair and Luforbec) contain extrafine beclometasone dipropionate.1,2,5,6,10,11
Of the three manufacturers only Cipla has an extrafine beclometasone product – Kelhale (beclometasone dipropionate).9,12,13 For Kelhale prescribing information, click here.
Bibecfo 100/6mcg can be used as both a Maintenance and Reliever therapy, in line with asthma guidelines 8,14,15
Maintenance and Reliever Therapy, or MART, is a type of asthma treatment plan in which patients have just one inhaler to maintain asthma control with a daily maintenance dose, and to relieve any asthma symptoms.1
At less than half the price of Fostair, Bibecfo 100/6mcg combination pMDI may offer a more affordable option to this treatment plan. This could reduce the burden on NHS budgets or allow more patients to get the treatment they need.3
Fostair is a registered trademark of Chiesi Ltd.
Luforbec is a registered trademark of Lupin Ltd
Bibecfo indications
Bibecfo 100/6mcg and 200/6mcg are indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting β₂-agonist) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled rapid-acting β₂-agonist
or
- patients already adequately controlled on both inhaled corticosteroids and long-acting β₂-agonists.1,2
Bibecfo 100/6mcg is indicated in the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.1
Bibecfo 100/6mcg and 200/6mcg are indicated in adults 18 years and above. For Bibecfo 100/6mcg in asthma, no recommendation on a dose can be made in children and adolescents 17 years and under.
Bibecfo doses
Adults 18 years and older:
100/6mcg1
Asthma (Maintenance therapy):
One or two inhalations twice daily
Maximum daily dose is 4 inhalations
Asthma (Maintenance and reliever therapy):
One inhalation twice daily with one additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken
Maximum daily dose is 8 inhalations
COPD:
Two inhalations twice daily
200/6mcg2
Asthma (Maintenance therapy):
Two inhalations twice daily
Maximum daily dose is 4 inhalations